Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system
Blacklock, J.B.; Grimm, E.A.
Immunology Series 48: 93-99
1989
ISSN/ISBN: 0092-6019 PMID: 2488328 Document Number: 336771
Document emailed within 1 workday
Related Documents
Lamers, H.J.; Gratama, J.W.; van Putten, W.L.; Stoter, G.; Bolhuis, R.L. 1991: Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes Cancer Research 51(9): 2324-2328Thompson, J.A.; Benyunes, M.C.; Bianco, J.A.; Fefer, A. 1993: Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells Seminars in Oncology 20(6 Suppl 9: 46-51
Glassman, A.B. 1989: Interleukin-2 and lymphokine activated killer cells: promises and cautions Annals of Clinical and Laboratory Science 19(1): 51-55
Sniecinski, I.J. 1989: Lymphokine-activated killer lymphocytes: extramural clinical trials Immunology Series 48: 59-77
Itoh, K.; Tilden, A.B.; Kumagai, K.; Balch, C.M. 1985: Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells Journal of Immunology 134(2): 802-807
Kanai, T.; Monden, M.; Takeda, T.; Gotoh, M.; Sakon, M.; Umeshita, K.; Hasuike, Y.; Sakita, I.; Nakano, H.; Yoshida, T. 1993: Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(11): 1457-1460
Kaufmann, Y.; Levanon, M.; Davidsohn, J.; Ramot, B. 1987: Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity Journal of Immunology 139(3): 977-982
Stewart, J.A.; Belinson, J.L.; Moore, A.L.; Dorighi, J.A.; Grant, B.W.; Haugh, L.D.; Roberts, J.D.; Albertini, R.J.; Branda, R.F. 1990: Phase i trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer Cancer Research 50(19): 6302-6310
Marincola, F.M.; Da Pozzo, L.F.; Drucker, B.J.; Holder, W.D. 1990: Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model Surgery 108(5): 919-929
Marcus, S.L.; Dutcher, J.P.; Paietta, E.; Ciobanu, N.; Strauman, J.; Wiernik, P.H.; Hutner, S.H.; Frank, O.; Baker, H. 1987: Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells Cancer Research 47(15): 4208-4212
Silver, R.M. 1990: Lymphokine activated killer (LAK) cell activity in the peripheral blood lymphocytes of systemic sclerosis (SSc) patients Clinical and Experimental Rheumatology 8(5): 481-486
Shiloni, E.; Lafreniere, R.; Mulé, J.J.; Schwarz, S.L.; Rosenberg, S.A. 1986: Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice Cancer Research 46(11): 5633-5640
Yasumoto, K.; Mivazaki, K.; Nagashima, A.; Ishida, T.; Kuda, T.; Yano, T.; Sugimachi, K.; Nomoto, K. 1987: Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer Cancer Research 47(8): 2184-2187
Takahashi, M. 1991: Specific antitumor effect of lymphokine-activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of interleukin-2 (IL-2) Nihon Geka Gakkai Zasshi 92(3): 247-256
Sznol, M.; Clark, J.W.; Smith, J.W.; Steis, R.G.; Urba, W.J.; Rubinstein, L.V.; VanderMolen, L.A.; Janik, J.; Sharfman, W.H.; Fenton, R.G. 1992: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma Journal of the National Cancer Institute 84(12): 929-937
Weil-Hillman, G.; Voss, S.D.; Fisch, P.; Schell, K.; Hank, J.A.; Sosman, J.A.; Sugamura, K.; Sondel, P.M. 1990: Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype Cancer Research 50(9): 2683-2691
Merluzzi, V.J.; Trail, P.A.; Last-Barney, K. 1986: Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow Journal of Immunology 137(8): 2425-2427
Sondel, P.M.; Hank, J.A.; Kohler, P.C.; Chen, B.P.; Sosman, J. 1989: "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes Progress in Clinical and Biological Research 288: 151-160
Jíra, M.; Malkovský, M.; Denman, A.M.; Loveland, B.; Lyons, D.; Dalgleish, A.G.; Webster, A.D. 1987: Lymphokine-activated killer cell activity in rheumatoid arthritis Clinical and Experimental Immunology 68(3): 535-542
Hamada, F.; Fuchimoto, S.; Orita, K. 1989: Suppression of lymphokine activated killer (LAK) cells by immunosuppressive substance Research Communications in Chemical Pathology and Pharmacology 65(1): 81-95